1. Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures
- Author
-
Aleksei A. Stepanenko, Anastasiia O. Sosnovtseva, Marat P. Valikhov, Anastasia A. Chernysheva, Sergey A. Cherepanov, Gaukhar M. Yusubalieva, Zsolt Ruzsics, Anastasiia V. Lipatova, and Vladimir P. Chekhonin
- Subjects
Cancer Research ,viruses ,glioblastoma ,DNX-2401 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Ad5-delta-24-RGD ,biochemical phenomena, metabolism, and nutrition ,gene therapy ,Oncology ,Ad5/35 ,glioma ,Molecular Medicine ,Original Article ,fiber chimeric adenovirus ,Pharmacology (medical) ,immunotherapy ,oncolytic virotherapy ,Ad5/3 ,RC254-282 - Abstract
Ad5-delta-24-RGD is currently the most clinically advanced recombinant adenovirus (rAd) for glioma therapy. We constructed a panel of fiber-modified rAds (Ad5RGD, Ad5/3, Ad5/35, Ad5/3RGD, and Ad5/35RGD, all harboring the delta-24 modification) and compared their infectivity, replication, reproduction, and cytolytic efficacy in human and rodent glioma cell lines and short-term cultures from primary gliomas. In human cells, both Ad5/35-delta-24 and Ad5/3-delta-24 displayed superior infectivity and cytolytic efficacy over Ad5-delta-24-RGD, while Ad5/3-delta-24-RGD and Ad5/35-delta-24-RGD did not show further improvements in efficacy. The expression of the adenoviral receptors/coreceptors CAR, DSG2, and CD46 and the integrins αVβ3/αVβ5 did not predict the relative cytolytic efficacy of the fiber-modified rAds. The cytotoxicity of the fiber-modified rAds in human primary normal cultures of different origins and in primary glioma cultures was comparable, indicating that the delta-24 modification did not confer tumor cell selectivity. We also revealed that CT-2A and GL261 glioma cells might be used as murine cell models for the fiber chimeric rAds in vitro and in vivo. In GL261 tumor-bearing mice, Ad5/35-delta-24, armed with the immune costimulator OX40L as the E2A/DBP-p2A-mOX40L fusion, produced long-term survivors, which were able to reject tumor cells upon rechallenge. Our data underscore the potential of local Ad5/35-delta-24-based immunovirotherapy for glioblastoma treatment., Graphical abstract, The oncolytic fiber chimeric recombinant adenoviruses based on serotype 5 with the fiber proteins consisting of the shaft and/or knob domains derived from serotypes 3 or 35 display superior infectivity and cytolytic efficacy over clinically advanced Ad5-delta-24-RGD in human brain tumor (glioblastoma) cultures.
- Published
- 2022
- Full Text
- View/download PDF